HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Health Sciences / Faculty of Health Sciences >
Peer-reviewed Journal Articles, etc >

Prediction of Response to Treatment by Gene Expression Profiling of Peripheral Blood in Patients with Microscopic Polyangiitis

This item is licensed under: Creative Commons Attribution 3.0 Unported

Files in This Item:
journal.pone.0063182.pdf490.63 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/53034

Title: Prediction of Response to Treatment by Gene Expression Profiling of Peripheral Blood in Patients with Microscopic Polyangiitis
Authors: Ishizu, Akihiro Browse this author →KAKEN DB
Tomaru, Utano Browse this author →KAKEN DB
Murai, Taichi Browse this author
Yamamoto, Tomohiro Browse this author
Atsumi, Tatsuya Browse this author →KAKEN DB
Yoshiki, Takashi Browse this author →KAKEN DB
Yumura, Wako Browse this author
Yamagata, Kunihiro Browse this author →KAKEN DB
Yamada, Hidehiro Browse this author →KAKEN DB
Kumagai, Shunichi Browse this author →KAKEN DB
Kurokawa, Manae S. Browse this author →KAKEN DB
Suka, Machi Browse this author →KAKEN DB
Makino, Hirofumi Browse this author →KAKEN DB
Ozaki, Shoichi Browse this author →KAKEN DB
Issue Date: 17-May-2013
Publisher: Public Library of Science
Journal Title: PLoS One
Volume: 8
Issue: 5
Publisher DOI: 10.1371/journal.pone.0063182
Abstract: The JMAAV study was an open-labeled prospective clinical trial, which proposed severity-based treatment protocols for patients with microscopic polyangiitis (MPA). The results suggest that the proposed protocols are useful (remission rate: 89.4%), but are also indicative of relapse or patient demise regardless of the treatment (recurrence rate: 19.0%; mortality rate: 10.6%). The aim of this study is to develop the method to predict response to the treatment in patients with MPA. In the present study, transcriptome analysis was performed using peripheral blood from patients enrolled in the JMAAV study before and 1-week after the beginning of treatment. The gene expression profile before treatment was not directly related to the response to the treatment. However, when the samples from 9 patients with good response (persistent remission for 18 months) were examined, the expression of 88 genes was significantly altered by the treatment. Thirty statistically reliable genes were selected, and then the alteration of expression by the treatment was examined among 22 patients, including 17 with good response, which was defined as persistent remission for 18 months and 5 with poor response, which was defined as relapse after remission or no remission. Discrimination analysis between the alteration of expression of the 30 genes by the treatment and the response identified a combination of 16 genes as the most valuable gene set to predict the response to the treatment. This preliminary study identified IRF7, IFIT1, IFIT5, OASL, CLC, GBP-1, PSMB9, HERC5, CCR1, CD36, MS4A4A, BIRC4BP, PLSCR1, DEFA1/DEFA3, DEFA4, and COL9A2 as the important genes that can predict the response to the treatment in patients with MPA at an early point during the therapy.
Rights: http://creativecommons.org/licenses/by/3.0/
Type: article
URI: http://hdl.handle.net/2115/53034
Appears in Collections:保健科学院・保健科学研究院 (Graduate School of Health Sciences / Faculty of Health Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 石津 明洋

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University